{"entity":{"id":"nct04521413","kind":"trial","name":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Treadwell Therapeutics, Inc, active and no longer recruiting.","summary":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT04521413 by Treadwell Therapeutics, Inc, with 170 participants enrolled, started 2020-08-31 and due to reach its primary completion in 2025-11. Interventions recorded: CFI-402411 and Pembrolizumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04521413","url":"https://clinicaltrials.gov/study/NCT04521413"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["treadwell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04521413","phase":"1/2","setting":"A First-In-Human, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies","sponsor":"Treadwell Therapeutics, Inc","participation":[{"nct":"NCT04521413","source":"https://clinicaltrials.gov/study/NCT04521413","fetchedAt":"2026-10-07T16:53:21.850Z","studySha256":"41e77e06fb79c2fc56338f58a720286a007298ef1ba610288386abebfe98690b","overallStatus":"UNKNOWN","lastUpdatePosted":"2025-05-21","leadSponsor":"Treadwell Therapeutics, Inc","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":170,"enrolmentType":"ESTIMATED","siteCount":13,"recruitingSiteCount":0,"countries":["Canada","Hong Kong","United States"]}],"started":"2020-08-31","startedType":"actual","enrolled":170,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04521413/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/"}]}}